Translation of genomics into routine cardiological practice

 Session 1 – Exemplars of translation into clinical practice and lessons learnt

 Moderators tbc

14:00 - 14:10

Welcome - Introduction - Objectives of the Workshop

To prepare a short position paper describing:

1. Current state of the art in genetic diagnostics and therapy.
2. Describe the current and future barriers to translation.
3. Propose an action plan to accelerate into routine care.                                                                               

Chairpersons

14:10 - 14:30

What is precision cardiology?

Perry Elliott (London)

14:30 - 14:45

PCSK9 and beyond

Ulf Landmesser (Berlin)

14:45 - 15:00

Cardiac Amyloidosis

Marianna Fontana (London) TBC

15:00- 15:45

Breakout Groups & Feedback/discussion (1)

What does success look like?

Moderators

Session 2 – CURRENT STATE OF THE ART: CHALLENGES FOR GENE THERAPY

Moderators tbc

15:45 - 16:00

Challenges for gene therapies: Delivery, durability and complications

Mauro Giacca (London)

16:00 - 16:15

Gene therapy and Gene editing
Examples of successful translation

Christian Kupatt (Munich)

16:15 - 16:30
10‘talk+10‘ disc.

RNA Therapeutics

Speaker from Alnylam

16:30-17:15

Breakout Groups & Feedback/discussion  (2)

1. What are the main technical/biological barriers to be overcome?

2. What can we do collectively to accelerate translation to patients?

Moderators

17:15 - 17:30

Break

Session 3 – DIAGNOSTICS: POLYGENIC RISK SCORES

17:30 - 17:45
10‘talk+10‘ Disc

Debate: Polygenic risk scores are ready for application in routine cardiological practice.

Pro: Speaker TBC

17:45 - 18:00
10‘talk+10‘ Disc

Debate: Polygenic risk scores are ready for application in routine cardiological practice.

Con: Heribert Schunkert (Munich)

Panel and audience discussion “How to overcome the gaps in translation – What are the critical issues?”

18:00 – End of Day  1 - Outlook to Day 2

Session 3 (cont’d) – DIAGNOSTICS: POLYGENIC RISK SCORES

Challenges and opportunities - A 5’ introduction for each topic and 15’ discussion

09:00 - 09:20

What does a gene therapy trial look like?

Speaker TBC

09:20 - 09:40

What is the landscape for approval and licensing of genomic therapies (FDA, EMA, MHRA)

Antonio Gomez-Outes (Spain)

Emmanouil Zouridakis, UK MHRA

Sairah Tommy (USA) FDA

09:40 - 10:40

Breakout Groups & Feedback/discussion (3)

1. How do we prioritize diseases for gene therapy?
2. What are meaningful end-points in gene trials
3. What should professional societies/organizations be doing to prepare for precision diagnostics and therapy in CVD?

Moderators

10:40 - 11:00

Break

11:00 - 11:45

Wrap-up from breakout groups – Call for actions?
Key take-home messages and
Recommendations in preparation of a publication

Chairpersons

12:00 – End of Day  2